SCHEMBL6499256

SCHEMBL6499256

O=C(O)CCC(O)c1cccs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
KMT2A Q03164 2/20 0.48
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
KEAP1 Q14145 1/20 0.46
HPGD P15428 2/20 0.44
ALDH1A1 P00352 4/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.43
POLB P06746 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
HTR1A P08908 1/20 0.42
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
SLC5A2 P31639 1/20 0.40
ALOX5 P09917 1/20 0.39
LTB4R Q15722 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4440609 0.82 NPC1 (0.57) NPC1RAB9AKMT2ACES2CES1
SCHEMBL11544964 0.82 HPGD (0.44) NPC1RAB9AKMT2ACES2CES1
Butyric Acid SCHEMBL27783903 0.82 KMT2A (0.43) NPC1RAB9AKMT2ACES2CES1
SCHEMBL4446826 0.81 CES2 (0.49) NPC1RAB9AKMT2ACES2CES1
SCHEMBL28316937 0.81 CES2 (0.49) NPC1RAB9AKMT2ACES2CES1
SCHEMBL3962690 0.81 CES2 (0.49) NPC1RAB9AKMT2ACES2CES1
SCHEMBL4368395 0.81 HPGD (0.46) NPC1RAB9AKMT2ACES2CES1
SCHEMBL21381235 0.81 CYP2C19 (0.43) NPC1RAB9AKMT2ACES2CES1
Ethane SCHEMBL4831611 0.79 CES2 (0.46) NPC1RAB9AKMT2ACES2CES1
SCHEMBL5286958 0.78 RAB9A (0.44) NPC1RAB9AKMT2ACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) 2005-05-26 US claimed
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses GABRB1, GABRA1, GABRA5 NPC1 2463/4885RAB9A 3126/4885KMT2A 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.